Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.75 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.73 |
| ▸ | TNF | P01375 | 3/20 | 0.73 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.73 |
| ▸ | IL1B | P01584 | 2/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.54 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.54 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727974 | 1.00 | CRBN (0.75) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL19436868 | 1.00 | CRBN (0.75) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL19612027 | 0.93 | CRBN (0.65) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL19612028 | 0.93 | CRBN (0.65) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL25031818 | 0.86 | CRBN (0.77) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL29453150 | 0.86 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL31727916 | 0.86 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL1097880 | 0.86 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL19973047 | 0.86 | CRBN (0.77) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL20442491 | 0.86 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712974-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709370-A2 | STAT DEGRADERS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4562007-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923394-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119451950-A | Compounds and methods for degrading casein kinase 1 alpha | 匹恩治疗株式会社 | 2025-02-14 | — | — | CN | disclosed |
| CN-119350363-A | PROTAC molecules and application thereof | 中国药科大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119264119-A | Preparation method and application of FLT3 degradation agent based on pyrazinecarboxamide skeleton | 中国科学院上海有机化学研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-113979999-B | Compound for targeted ubiquitination degradation of BCR-ABL kinase and preparation method, composition and application thereof | 北京鑫开元医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| CN-114341128-A | Bifunctional protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114286678-A | Compounds for inhibiting and inducing degradation of EGFR and ALK | 北京泰德制药股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114174299-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3952871-A1 | DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3947368-A1 | CDK2/5 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113979999-A | Compound for targeted ubiquitination degradation of BCR-ABL kinase and preparation method, composition and application thereof | 北京鑫开元医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2022017442-A1 | BIFUNCTIONAL PROTEIN DEGRADATION-TARGETED CHIMERA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2022-01-27 | — | — | WO | disclosed |